Rockefeller Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Rockefeller Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10	Closed	–	–	3209
2022 Q4	$0	Hold	10	–	–	﹤0.01%	4090
2022 Q3	$0	Buy	+10	New	+$595	﹤0.01%	4214
2021 Q3	–	Sell	-27	Closed	-$6K	–	3797
2021 Q2	$6K	Hold	27	–	–	﹤0.01%	2980
2021 Q1	$8K	Hold	27	–	–	﹤0.01%	2695
2020 Q4	$6K	Sell	27 -15	-36%	-$3.88K	﹤0.01%	2382
2020 Q3	$10K	Buy	42 +6	+17%	+$1.89K	﹤0.01%	2017
2020 Q2	$13K	Sell	36 -8	-18%	-$2.5K	﹤0.01%	1817
2020 Q1	$12K	Buy	44 +16	+57%	+$4.95K	﹤0.01%	1688
2019 Q4	$9K	Buy	28 +1	+4%	+$290	﹤0.01%	1639
2019 Q3	$7K	Buy	+27	New	+$9.9K	﹤0.01%	1533
2019 Q2	–	Sell	-15	Closed	-$8K	–	1863
2019 Q1	$8K	Buy	+15	New	+$8.89K	﹤0.01%	1536

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rockefeller Capital Management's NKTR Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 10 shares.

Rockefeller Capital Management first reported a position in NKTR in Q1 2019 and held it in 11 quarters. The position peaked at $13K in Q2 2020. 194 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

Rockefeller Capital Management reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
Rockefeller Capital Management sold 10 Nektar Therapeutics shares in Q1 2023.
Rockefeller Capital Management first reported a position in Nektar Therapeutics in Q1 2019 and held it in 11 quarters.
Rockefeller Capital Management's Nektar Therapeutics position peaked at $13K in Q2 2020.
194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.